Find a trial

At Icon, we offer clinical trials across various tumour types and blood disorders, allowing patients access to new and emerging advances in treatment, find a trial that might be suitable for you.


Use the search function below to find a clinical trial that may suit you and your cancer diagnosis

+ Advanced

ADG206-1001

A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects with Advanced/Metastatic Solid Tumors

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

SKB264-II-06

A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Locations

Wesley

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

SHR-A1921-I-102

A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1921 in Subjects With Advanced Malignant Solid Tumour .

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

BGB-A317-26808-101

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

BGB-24714-101

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced or Metastatic Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

RC198-G001

A Phase 1, First-In-Human, Multicenter, Open-Label Study in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Locations

Wesley

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

IL Believe

A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Locations

Farrer Park

Diagnosis

Advanced solid tumours, Cervical cancer, Lung cancer, Skin cancer – melanoma

Open for recruitment
View Trial

BBI-TP-3654-102

A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis

Locations

Adelaide (Windsor Gardens)

Diagnosis

Myeloproliferative disorders

Open for recruitment
View Trial

PXS5505-MF-101

A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Locations

Adelaide (Kurralta Park)

Diagnosis

Myeloproliferative disorders

Open for recruitment
View Trial

DB-1303-O-1001

A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients With Advanced/Metastatic Solid Tumors. (DB-1303-O-1001)

Locations

South Brisbane

Diagnosis

Breast cancer, Endometrial cancer

Open for recruitment
View Trial

BGB-A317-A3055-101

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

AK127-101

A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumour Activity of AK127 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumours

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

STARSTRUCK 177Lu-TLX250-001

A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and peposertib in Patients with Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

HMDB-001-003

A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-small Cell Lung Cancers

Locations

South Brisbane

Diagnosis

Lung cancer

Open for recruitment
View Trial

HMDB-001-002

A Phase 1b Study to Evaluate HMBD-001 With or Without Chemotherapy in Participants With Advanced Solid Tumors Harboring NRG1 Gene Fusions or Selected HER3 Mutations

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

ZN-c3-004

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma

Locations

Chermside

Diagnosis

Endometrial cancer

Open for recruitment
View Trial

ZN-c3-005

A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (ZN-c3-005/GOG-3066/DENALI)

Locations

Chermside

Diagnosis

Ovarian cancer

Open for recruitment
View Trial

BA3011-002

A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD-1/L1, EGFR, or ALK Inhibitor

Locations

Central Building (Oncology)

Diagnosis

Lung cancer

Open for recruitment
View Trial

ASPEN-06 AT148006

A Phase 2/3 Study of ALX148 in Patients with Advanced HER2- Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

Locations

Southport

Diagnosis

Gastric / gastroesophageal cancer

Open for recruitment
View Trial

OLYMPIA-3 R1979-ONC-2105

A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (O-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)

Locations

Wesley

Diagnosis

Lymphoma – B-cell Non Hodgkin’s

Open for recruitment
View Trial

OLYMPIA-1 R1979-HM-2298

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator’s Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)

Locations

Wesley

Diagnosis

Lymphoma – B-cell Non Hodgkin’s

Open for recruitment
View Trial

Viktoria-1 CELC-G-301

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy

Locations

Southport

Diagnosis

Breast cancer

Open for recruitment
View Trial

Viktoria-1

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy

Locations

Farrer Park

Diagnosis

Breast cancer

Open for recruitment
View Trial

RAMP 301 VS-6766-301

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator’s Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)

Locations

Wesley

Diagnosis

Ovarian cancer

Open for recruitment
View Trial

VERITAC-2 C4891001

A Phase 3, Randomized, Open-Label, Multicenter Trial of ARV-471 (PF-07850327) VS Fulvestrant in Participants with Estrogen Receptor-Positive, HER-2-Negative Advanced Breast Cancer whose Disease Progressed after Prior Endocrine Based Treatment for Advanced Disease (VERITAC-2)

Locations

Hobart, Adelaide (Kurralta Park), Adelaide (Windsor Gardens)

Diagnosis

Breast cancer

Open for recruitment
View Trial

RADIANT BAY 88-8223 / 20510

A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Novel Anti-hormonal Therapy (NAH) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRPC) Progressing on/After One Line of NAH

Locations

Adelaide (Kurralta Park)

Diagnosis

Prostate cancer

Open for recruitment
View Trial

CS5001-101

A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors and Lymphomas

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours, Lymphoma – B-cell Non Hodgkin’s, Lymphoma – T-Cell Non Hodgkin’s, Lymphoma – Hodgkin’s

Open for recruitment
View Trial

APG-2449-OG-101

A Phase Ib/II Study of APG-2449 in Combination with Doxorubicin Hydrochloride Liposome in Patients with Ovarian Cancer

Locations

South Brisbane

Diagnosis

Ovarian cancer

Open for recruitment
View Trial

CAPTURE BCT1901

A phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced breast cancer patients with PIK3CA mutant circulating DNA.

Locations

Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial

CO44194

A Phase II, Multicenter, Randomized, Double-Blind Study of RO7247669 Combined with Nab-Paclitaxel compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Locations

Adelaide (Windsor Gardens)

Diagnosis

Breast cancer

Open for recruitment
View Trial

BO44157

A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy

Locations

Adelaide (Kurralta Park)

Diagnosis

Urothelial cancer

Open for recruitment
View Trial

CAPItello-280

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Locations

Adelaide (Kurralta Park)

Diagnosis

Prostate cancer

Open for recruitment
View Trial

INAVO122

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Locations

Farrer Park

Diagnosis

Breast cancer

Open for recruitment
View Trial

INAVO121 WO43913

A Phase III, Multicenter, Randomized, Open-Label Study Evaluation the Efficacy and Safety of Inavolisib plus Fulvestrant versus Alpelisib plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer who Progressed during or after CDK4/6 Inhibitor and Endocrine Combination Therapy

Locations

Wesley

Diagnosis

Breast cancer

Open for recruitment
View Trial

CAMBRIA-1

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer

Locations

Farrer Park

Diagnosis

Breast cancer

Open for recruitment
View Trial

SB221

A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients with Platinum-Resistant Ovarian Cancer

Locations

Adelaide (Kurralta Park)

Diagnosis

Ovarian cancer

Open for recruitment
View Trial

BO43936

A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Locations

Adelaide (Kurralta Park)

Diagnosis

Kidney cancer

Open for recruitment
View Trial

STELLAR 303

A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Locations

Farrer Park

Diagnosis

Colorectal cancer

Open for recruitment
View Trial

EvoPAR-Prostate01 D9723C00001

A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)

Locations

Townsville, Chermside, Adelaide (Kurralta Park)

Diagnosis

Prostate cancer

Open for recruitment
View Trial

HLX10-020-SCLC302

A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Locations

Wesley

Diagnosis

Lung cancer

Open for recruitment
View Trial

CL-SBP-101-04

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

Locations

Adelaide (Kurralta Park)

Diagnosis

Pancreatic cancer

Open for recruitment
View Trial

ASCENT-07 GS-US-598-6168

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy

Locations

Hobart, Wesley

Diagnosis

Breast cancer

Open for recruitment
View Trial

C-POST R2810-ONC-1788

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Locations

Southport, Adelaide (Kurralta Park)

Diagnosis

Skin cancer – non-melanoma

Open for recruitment
View Trial

BGB-A317-LBL-007-201

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer

Locations

South Brisbane

Diagnosis

Colorectal cancer

Open for recruitment
View Trial

AK104-212

A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer

Locations

South Brisbane, Chermside

Diagnosis

Lung cancer

Open for recruitment
View Trial

Relativity-106

A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (RELATIVITY-106)

Locations

Farrer Park

Diagnosis

Liver cancer

Open for recruitment
View Trial

BRIGHTLINE-1

A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Locations

Adelaide (Kurralta Park)

Diagnosis

Sarcoma

Open for recruitment
View Trial

C4391022

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Locations

Townsville

Diagnosis

Breast cancer

Open for recruitment
View Trial

AML M22

AMLM22/D1: The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.

Locations

South Brisbane, Wesley, Chermside, Southport

Diagnosis

Leukaemia

Open for recruitment
View Trial

REGENERON_ R1979-ONC-1625

An open-label study to assess the anti-tumor activity and safety of REGN1979, an Anti-CD20 X Anti-CD3 bispecific antibody, in patients with relapsed or refractory B-cell non-hodgkin lymphoma

Locations

Farrer Park

Diagnosis

Lymphoma – B-cell Non Hodgkin’s

Open for recruitment
View Trial

VNC-236-101

An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity and Pharmacokinetics of VIP236 Monotherapy in Subjects With Advanced Cancer

Locations

South Brisbane, Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

LINKER-MM3 R5458-ONC-2245

An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)

Locations

Wesley

Diagnosis

Multiple myeloma

Open for recruitment
View Trial

CLINCH ATG-022-ST-001

An Open, Multi-center, Phase I Clinical Study of ATG-022 in Patients with Advanced/metastatic Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

ALLG NBCR

Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry

Locations

Wesley

Diagnosis

Leukaemia

Open for recruitment
View Trial

LIBERATE

Clinical registry of focal low dose rate brachytherapy in men with biopsy confirmed low-intermediate risk prostate cancer (LIBERATE)

Locations

Epworth Richmond, Epworth Freemasons, Geelong

Diagnosis

Prostate cancer

Open for recruitment
View Trial

CONSOLE

Conventional or Stereotactic Radiotherapy for the palliation of non-spine bone metastases: A randomised phase III trial.

Locations

Wahroonga, Gold Coast University Hospital, Gold Coast Private, Epworth Richmond, Epworth Freemasons, Mulgrave, Hobart

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

DECREASE TROG 19.06

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

Locations

Epworth Richmond

Diagnosis

Prostate cancer

Open for recruitment
View Trial

PHI-101-001

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML

Locations

Wesley

Diagnosis

Leukaemia

Open for recruitment
View Trial

EXPERT BCT1601

EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer (EXPERT)

Locations

Epworth Richmond

Diagnosis

Breast cancer

Open for recruitment
View Trial

ERUPT

External beam Radiotherapy and Urethral strictures in Prostate cancer Treatment (ERUPT)

Locations

Toowoomba

Diagnosis

Prostate cancer

Open for recruitment
View Trial

AMT-116-01

First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

AMT-151-01

First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

HyperArc Registry VAR-2019-01

HyperArc Registry Study

Locations

Canberra, Greenslopes, Gold Coast Private, Maroochydore

Diagnosis

Brain cancer

Open for recruitment
View Trial

I-MAT MASC 03.18

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

Locations

Hobart

Diagnosis

Skin cancer – non-melanoma

Open for recruitment
View Trial

BOREAS KRT-232-101

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

Locations

South Brisbane, Wesley

Diagnosis

Myeloproliferative disorders

Open for recruitment
View Trial

MASTERPLAN

MASTERPLAN: A Randomised Phase II Study of MFOLFIRINOX and Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer with High Risk and Locally Advanced Disease

Locations

Gold Coast University Hospital

Diagnosis

Pancreatic cancer

Open for recruitment
View Trial

MRDR

Myeloma and Related Disease Registry

Locations

Wesley, South Brisbane, Chermside, Southport

Diagnosis

Multiple myeloma

Open for recruitment
View Trial

OPTIMA BCT 2202

Optimal personalised treatment of early breast cancer using multiparameter analysis

Locations

Southport, Wesley, Hobart, Adelaide (Kurralta Park), Adelaide (Windsor Gardens)

Diagnosis

Breast cancer

Open for recruitment
View Trial

SLN124-004

Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera

Locations

Adelaide (Kurralta Park)

Diagnosis

Myeloproliferative disorders

Open for recruitment
View Trial

KRYSTAL-10

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation

Locations

Farrer Park

Diagnosis

Colorectal cancer

Open for recruitment
View Trial

HARMONY R3767-ONC-2011

Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Locations

Hobart

Diagnosis

Skin cancer – melanoma

Open for recruitment
View Trial

ARTISTRY-7 ALKS 4230-007

Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Locations

Wesley

Diagnosis

Ovarian cancer

Open for recruitment
View Trial

KEYNOTE-867 MK-3475-867

Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC)

Locations

Hobart

Diagnosis

Lung cancer

Open for recruitment
View Trial

JSKN033-101

Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and efficacy of JSKN033 in Patients with Advanced or Metastatic Solid Malignant Tumours

Locations

Wesley

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

ANZadapt

Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC (ANZadapt)

Locations

Adelaide (Kurralta Park), Adelaide (Windsor Gardens)

Diagnosis

Prostate cancer

Open for recruitment
View Trial

FIG / TROG 18.06

Prospective, multicentre trial evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine Positron Emission Tomography in Glioblastoma (FET-PET in Glioblastoma)

Locations

Wesley

Diagnosis

Brain cancer

Open for recruitment
View Trial

ASCENT-04 GS-US-592-6173

Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1

Locations

Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial

ASCENT-03 GS-US-592-6238

Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1

Locations

Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial

TREMOR

Safety and effectiveness of frameless linac-based stereotactic radiosurgery on tremor in patients with essential tremor or Parkinson’s disease (TREMOR study)

Locations

Epworth Richmond

Diagnosis

Neurological conditions

Open for recruitment
View Trial

KEYVIBE-006 MK-7684A-006

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer

Locations

Hobart

Diagnosis

Lung cancer

Open for recruitment
View Trial

SUNRAY-01 J3M-MC-JZQB

SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression

Locations

Wesley

Diagnosis

Lung cancer

Open for recruitment
View Trial

ROSEND

The ROSEND Trial – A Randomised trial for the treatment of recalcitrant symptomatic rosacea using definitive volumetric modulated arc radiotherapy or standard dermatological treatment

Locations

Revesby, Wahroonga, Gosford

Diagnosis

Skin cancer – non-melanoma

Open for recruitment
View Trial

ABCPro

Trial is evaluating a new online service for managing self-reported symptoms by people with advanced breast cancer.

Locations

Bowen Icon Cancer Centre

Diagnosis

Breast cancer

Open for recruitment
View Trial

TUGETHER BCT2102

Tucatinib together with Pembrolizumab and Trastuzumab: A Phase II, Two-Arm, Non-Comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab (MK-3475) and Trastuzumab in Patients with Pre-Treated Advanced HER2-Positive Breast Cancer

Locations

Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial
There are no clinical trials currently available

We are always introducing new clinical trials across our international network. If you can’t find what you are looking for please don’t hesitate to speak to your doctor to learn more, or contact us here.

Search

Contact us
Become a patient